{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:59:39Z","timestamp":1782230379627,"version":"3.54.5"},"reference-count":47,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The impact of direct-acting antivirals (DAA) therapy on lipid and glucose metabolism and kidney function in patients with hepatitis C virus (HCV) infection, along with its side effects on blood cells, remains controversial. Therefore, we conducted a study that enrolled 280 patients with HCV infection who achieved sustained virologic response after treatment with DAA therapy without ribavirin to evaluate the metabolic changes, renal function, and anemia risk based on real-world data. This study was an observational prospective study with a follow-up period of 12 weeks after the initiation of DAA therapy. Data on biochemical tests, renal function, blood counts, viral load, and host genomics were recorded before treatment and after 12 weeks of treatment with DAAs. DAA therapy reduced fibrosis-4 scores and improved liver function, with significant reductions in aspartate transaminase, alanine aminotransferase, and total bilirubin levels. However, DAA therapy slightly increased uric acid, cholesterol, and low-density lipoprotein cholesterol levels. It significantly reduced fasting blood glucose levels and hemoglobin A1C index (HbA1C) in the study group, while hemoglobin (Hb) and hematocrit (HCT) concentrations decreased significantly (4.78 \u00b1 21.79 g\/L and 0.09% \u00b1 0.11%, respectively). The estimated glomerular filtration rate (eGFR) decreased by 12.89 \u00b1 39.04 mL\/min\/1.73m<jats:sup>2<\/jats:sup>. Most variations were not related to the genotype, except for Hb, HCT, and HbA1C. Anemia incidence increased from 23.58% before treatment to 30.72% after treatment. Patients with HCV-1 genotype had a higher rate of anemia than did patients with genotype 6 (36.23% vs. 24.62%). Multivariate analysis showed that the risk of anemia was related to female sex, cirrhosis status, fibrosis-4 score, pretreatment eGFR, and pretreatment Hb level. The results of our study can provide helpful information to clinicians for the prognosis and treatment of HCV infection.<\/jats:p>","DOI":"10.1371\/journal.pone.0290235","type":"journal-article","created":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T17:29:52Z","timestamp":1693589392000},"page":"e0290235","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":7,"title":["Metabolic, renal, and hematological changes in chronic hepatitis C patients achieving rapid virologic response after 12 weeks of direct-acting antiviral treatment: A prospective cohort study"],"prefix":"10.1371","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0523-0852","authenticated-orcid":true,"given":"Phuong Nguyen","family":"Thi Thu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dung","family":"Hoang Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai","family":"Ngo Thi Quynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngan","family":"Tran Thi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2974-3484","authenticated-orcid":true,"given":"Khue","family":"Pham Minh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7107-1496","authenticated-orcid":true,"given":"Linh","family":"Pham Van","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2023,9,1]]},"reference":[{"issue":"5","key":"pone.0290235.ref001","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","article-title":"Electronic address eee, Clinical Practice Guidelines Panel C, representative EGB, Panel m. EASL recommendations on treatment of hepatitis C: Final update of the series().","volume":"73","author":"European Association for the Study of the Liver","year":"2020","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"pone.0290235.ref002","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0168-8278(99)80409-7","article-title":"Early predictors of response to treatment in patients with chronic hepatitis C","volume":"31","author":"MP Civeira","year":"1999","journal-title":"J Hepatol"},{"issue":"4","key":"pone.0290235.ref003","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0168-8278(02)00211-8","article-title":"Prognostic factors and early predictability of sustained viral response with peginterferon alfa-2a (40KD).","volume":"37","author":"SS Lee","year":"2002","journal-title":"J Hepatol"},{"issue":"13","key":"pone.0290235.ref004","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.3748\/wjg.v23.i13.2355","article-title":"Impact of interferon-free antivirus therapy on lipid profiles in patients with chronic hepatitis C genotype 1b","volume":"23","author":"D Endo","year":"2017","journal-title":"World J Gastroenterol"},{"key":"pone.0290235.ref005","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/IJGM.S127689","article-title":"Hepatitis C treatment: where are we now?","volume":"10","author":"NJ Burstow","year":"2017","journal-title":"Int J Gen Med"},{"issue":"1","key":"pone.0290235.ref006","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource","volume":"59","author":"DB Smith","year":"2014","journal-title":"Hepatology"},{"issue":"11","key":"pone.0290235.ref007","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1093\/infdis\/jiy401","article-title":"Identification of a Novel Hepatitis C Virus Genotype From Punjab, India: Expanding Classification of Hepatitis C Virus Into 8 Genotypes","volume":"218","author":"SM Borgia","year":"2018","journal-title":"J Infect Dis"},{"issue":"4","key":"pone.0290235.ref008","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/hep.20819","article-title":"Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes","volume":"42","author":"P Simmonds","year":"2005","journal-title":"Hepatology"},{"issue":"2","key":"pone.0290235.ref009","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1128\/JVI.01501-08","article-title":"Genetic history of hepatitis C virus in East Asia","volume":"83","author":"OG Pybus","year":"2009","journal-title":"J Virol"},{"issue":"6","key":"pone.0290235.ref010","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1053\/jhep.2001.24432","article-title":"Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity","volume":"33","author":"LE Adinolfi","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"pone.0290235.ref011","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/hep.21669","article-title":"FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest","volume":"46","author":"A Vallet-Pichard","year":"2007","journal-title":"Hepatology"},{"issue":"1","key":"pone.0290235.ref012","doi-asserted-by":"crossref","first-page":"10596","DOI":"10.1038\/s41598-019-46664-0","article-title":"Virus Genotype-Dependent Transcriptional Alterations in Lipid Metabolism and Inflammation Pathways in the Hepatitis C Virus-infected Liver.","volume":"9","author":"WMH d\u2019Avigdor","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"pone.0290235.ref013","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5604\/01.3001.0010.7536","article-title":"Worsening of Serum Lipid Profile after Direct Acting Antiviral Treatment.","volume":"17","author":"S Gitto","year":"2018","journal-title":"Ann Hepatol."},{"issue":"1","key":"pone.0290235.ref014","doi-asserted-by":"crossref","first-page":"13944","DOI":"10.1038\/s41598-021-93251-3","article-title":"Serum lipid profile in HCV patients treated with direct-acting antivirals: a systematic review and meta-analysis.","volume":"11","author":"R Villani","year":"2021","journal-title":"Sci Rep"},{"key":"pone.0290235.ref015","doi-asserted-by":"crossref","first-page":"631600","DOI":"10.3389\/fmed.2021.631600","article-title":"Metabolic Evaluation in Patients With Hepatitis C Treated With Direct Antiviral Agents.","volume":"8","author":"S Estefan","year":"2021","journal-title":"Front Med (Lausanne)."},{"key":"pone.0290235.ref016","article-title":"Lexicomp","author":"Drug Interactions","journal-title":"Wolters Kluwer Health IDi"},{"key":"pone.0290235.ref017","volume-title":"Chronic Hepatitis C Virus Advances in Treatment, Promise for the Future.:","author":"BB Kanwal F","year":"2011"},{"issue":"10","key":"pone.0290235.ref018","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1093\/cid\/ciy585","article-title":"Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"67","author":"A-IHG Panel","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"3","key":"pone.0290235.ref019","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus.","volume":"62","author":"Panel AIHG","year":"2015","journal-title":"Hepatology"},{"issue":"2","key":"pone.0290235.ref020","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1002\/hep.31060","article-title":"Panel A-IHCG. Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection","volume":"71","author":"MG Ghany","year":"2020","journal-title":"Hepatology"},{"issue":"2","key":"pone.0290235.ref021","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"CT Wai","year":"2003","journal-title":"Hepatology"},{"issue":"6","key":"pone.0290235.ref022","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"RK Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"pone.0290235.ref023","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"DW Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"pone.0290235.ref024","first-page":"5","article-title":"Report of a WHO scientific group.","volume":"405","author":"Nutritional anaemias","year":"1968","journal-title":"World Health Organ Tech Rep Ser"},{"key":"pone.0290235.ref025","author":"R: TR","year":"2005"},{"issue":"6","key":"pone.0290235.ref026","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3851\/IMP3117","article-title":"Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients.","volume":"22","author":"LI Backus","year":"2017","journal-title":"Antivir Ther"},{"issue":"8","key":"pone.0290235.ref027","doi-asserted-by":"crossref","first-page":"e41266","DOI":"10.1371\/journal.pone.0041266","article-title":"Hepatitis C virus in Vietnam: high prevalence of infection in dialysis and multi-transfused patients involving diverse and novel virus variants.","volume":"7","author":"L Dunford","year":"2012","journal-title":"PLoS One."},{"issue":"10","key":"pone.0290235.ref028","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1080\/17474124.2019.1653183","article-title":"Liver stiffness measurements and FIB-4 are predictors of response to sofosbuvir-based treatment regimens in 7256 chronic HCV patients.","volume":"13","author":"S Abdel Alem","year":"2019","journal-title":"Expert Rev Gastroenterol Hepatol."},{"issue":"3","key":"pone.0290235.ref029","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"JA Bachofner","year":"2017","journal-title":"Liver Int"},{"issue":"3","key":"pone.0290235.ref030","doi-asserted-by":"crossref","first-page":"258","DOI":"10.14218\/JCTH.2018.00014","article-title":"Hepatitis C Virus Clearance by Direct-acting Antiviral Results in Rapid Resolution of Hepatocytic Injury as Indicated by Both Alanine Aminotransferase and Aspartate Aminotransferase Normalization.","volume":"6","author":"T Huynh","year":"2018","journal-title":"J Clin Transl Hepatol."},{"issue":"11","key":"pone.0290235.ref031","doi-asserted-by":"crossref","first-page":"e0207043","DOI":"10.1371\/journal.pone.0207043","article-title":"Association of hyperuricemia with disease severity in chronic hepatitis C patients.","volume":"13","author":"TY Jang","year":"2018","journal-title":"PLoS One."},{"issue":"9","key":"pone.0290235.ref032","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1111\/j.1478-3231.2012.02842.x","article-title":"Hyperuricaemia: another metabolic feature affecting the severity of chronic hepatitis because of HCV infection","volume":"32","author":"S Petta","year":"2012","journal-title":"Liver Int"},{"issue":"7","key":"pone.0290235.ref033","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1080\/00365521.2018.1473486","article-title":"Lipids, glucose and iron metabolic alterations in chronic hepatitis C after viral eradication\u2014comparison of the new direct-acting antiviral agents with the old regimens","volume":"53","author":"JR Carvalho","year":"2018","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"pone.0290235.ref034","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2174\/1573399815666190531091128","article-title":"Evaluation of Glycated Haemoglobin (HbA1c) Level in Type 2 Diabetic Chronic HCV Non-cirrhotic Treatment-Naive Egyptian Patients Eradicated with Sofosbuvir Plus Daclatasvir.","volume":"16","author":"HA Hussein","year":"2020","journal-title":"Curr Diabetes Rev"},{"issue":"4","key":"pone.0290235.ref035","doi-asserted-by":"crossref","first-page":"e0231102","DOI":"10.1371\/journal.pone.0231102","article-title":"Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment.","volume":"15","author":"SM Chiu","year":"2020","journal-title":"PLoS One."},{"issue":"5","key":"pone.0290235.ref036","doi-asserted-by":"crossref","first-page":"e0268478","DOI":"10.1371\/journal.pone.0268478","article-title":"Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection.","volume":"17","author":"A O\u2019Donnell","year":"2022","journal-title":"PLoS One."},{"issue":"5","key":"pone.0290235.ref037","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1016\/j.cgh.2021.07.037","article-title":"Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR).","volume":"20","author":"CF Huang","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"pone.0290235.ref038","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s11739-020-02628-1","article-title":"Direct-acting antivirals improve kidney function in diabetic patients with HCV infection and chronic kidney disease.","volume":"16","author":"R Villani","year":"2021","journal-title":"Intern Emerg Med"},{"issue":"11","key":"pone.0290235.ref039","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/j.1440-1746.2004.03459.x","article-title":"Factors contributing to ribavirin-induced anemia","volume":"19","author":"H Nomura","year":"2004","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"pone.0290235.ref040","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1007\/s00535-003-1363-9","article-title":"Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C","volume":"39","author":"S Takaki","year":"2004","journal-title":"J Gastroenterol"},{"issue":"3","key":"pone.0290235.ref041","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/hep.26096","article-title":"Anemia during treatment with peginterferon Alfa-2b\/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.","volume":"57","author":"MS Sulkowski","year":"2013","journal-title":"Hepatology"},{"issue":"3","key":"pone.0290235.ref042","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/ejhpharm-2017-001277","article-title":"Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents.","volume":"25","author":"E Molina-Cuadrado","year":"2018","journal-title":"Eur J Hosp Pharm"},{"issue":"21","key":"pone.0290235.ref043","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","article-title":"ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis","volume":"370","author":"F Poordad","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0290235.ref044","first-page":"95","article-title":"Iron in hepatitis C: villain or innocent bystander?","volume":"13","author":"GN Ioannou","year":"2002","journal-title":"Semin Gastrointest Dis"},{"issue":"7","key":"pone.0290235.ref045","first-page":"986","article-title":"Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron","volume":"89","author":"H Hayashi","year":"1994","journal-title":"Am J Gastroenterol"},{"key":"pone.0290235.ref046","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.antiviral.2016.10.012","article-title":"Effectiveness and safety of sofosbuvir plus ribavirin for HCV genotype 2 patients 65 and over with or without cirrhosis","volume":"136","author":"E Ogawa","year":"2016","journal-title":"Antiviral Res"},{"issue":"2","key":"pone.0290235.ref047","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jhep.2011.02.023","article-title":"EASL Clinical Practice Guidelines: management of hepatitis C virus infection.","volume":"55","author":"European Association for the Study of the L.","year":"2011","journal-title":"J Hepatol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0290235","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T17:30:11Z","timestamp":1693589411000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0290235"}},"subtitle":[],"editor":[{"given":"Tyng-Yuan","family":"Jang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2023,9,1]]},"references-count":47,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0290235","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,1]]}}}